{"title":"姜黄素治疗血液肿瘤:前景与挑战","authors":"Maliheh Entezari , Armita Tayari , Mahshid Deldar Abad Paskeh , Simin Khorsand Kheirabad , Sahar Naeemi , Afshin Taheriazam , Hossein Dehghani , Shokooh Salimimoghadam , Mehrdad Hashemi , Sepideh Mirzaei , Saeed Samarghandian","doi":"10.1016/j.jtcme.2023.10.004","DOIUrl":null,"url":null,"abstract":"<div><p>Hematological cancers include leukemia, myeloma and lymphoma and up to 178.000 new cases are diagnosed with these tumors each year. Different kinds of treatment including radiotherapy, chemotherapy, immunotherapy and stem cell transplantation have been employed in the therapy of hematological cancers. However, they are still causing death among patients. On the other hand, curcumin as an anti-cancer agent for the suppression of human cancers has been introduced. The treatment of hematological cancers using curcumin has been followed. Curcumin diminishes viability and survival rate of leukemia, myeloma and lymphoma cells. Curcumin stimulates apoptosis and G2/M arrest to impair progression of tumor. Curcumin decreases levels of matrix metalloproteinases in suppressing cancer metastasis. A number of downstream targets including VEGF, Akt and STAT3 undergo suppression by curcumin in suppressing progression of hematological cancers. Curcumin stimulates DNA damage and reduces resistance of cancer cells to irradiation. Furthermore, curcumin causes drug sensitivity of hematological tumors, especially myeloma. For targeted delivery of curcumin and improving its pharmacokinetic and anti-cancer features, nanostructures containing curcumin and other anti-cancer agents have been developed.</p></div>","PeriodicalId":17449,"journal":{"name":"Journal of Traditional and Complementary Medicine","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2225411023001116/pdfft?md5=36b06bea4a56b44b2e924690885ea89c&pid=1-s2.0-S2225411023001116-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Curcumin in treatment of hematological cancers: Promises and challenges\",\"authors\":\"Maliheh Entezari , Armita Tayari , Mahshid Deldar Abad Paskeh , Simin Khorsand Kheirabad , Sahar Naeemi , Afshin Taheriazam , Hossein Dehghani , Shokooh Salimimoghadam , Mehrdad Hashemi , Sepideh Mirzaei , Saeed Samarghandian\",\"doi\":\"10.1016/j.jtcme.2023.10.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Hematological cancers include leukemia, myeloma and lymphoma and up to 178.000 new cases are diagnosed with these tumors each year. Different kinds of treatment including radiotherapy, chemotherapy, immunotherapy and stem cell transplantation have been employed in the therapy of hematological cancers. However, they are still causing death among patients. On the other hand, curcumin as an anti-cancer agent for the suppression of human cancers has been introduced. The treatment of hematological cancers using curcumin has been followed. Curcumin diminishes viability and survival rate of leukemia, myeloma and lymphoma cells. Curcumin stimulates apoptosis and G2/M arrest to impair progression of tumor. Curcumin decreases levels of matrix metalloproteinases in suppressing cancer metastasis. A number of downstream targets including VEGF, Akt and STAT3 undergo suppression by curcumin in suppressing progression of hematological cancers. Curcumin stimulates DNA damage and reduces resistance of cancer cells to irradiation. Furthermore, curcumin causes drug sensitivity of hematological tumors, especially myeloma. For targeted delivery of curcumin and improving its pharmacokinetic and anti-cancer features, nanostructures containing curcumin and other anti-cancer agents have been developed.</p></div>\",\"PeriodicalId\":17449,\"journal\":{\"name\":\"Journal of Traditional and Complementary Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-01-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2225411023001116/pdfft?md5=36b06bea4a56b44b2e924690885ea89c&pid=1-s2.0-S2225411023001116-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Traditional and Complementary Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2225411023001116\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Traditional and Complementary Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2225411023001116","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
血液肿瘤包括白血病、骨髓瘤和淋巴瘤,每年新确诊的血液肿瘤病例多达 17.8 万例。治疗血液肿瘤的方法多种多样,包括放疗、化疗、免疫疗法和干细胞移植。然而,这些疗法仍会导致患者死亡。另一方面,姜黄素作为一种抑制人类癌症的抗癌剂已经问世。使用姜黄素治疗血液癌症的研究一直在进行。姜黄素能降低白血病、骨髓瘤和淋巴瘤细胞的活力和存活率。姜黄素能刺激细胞凋亡和 G2/M 停滞,从而阻碍肿瘤的发展。姜黄素能降低基质金属蛋白酶的水平,从而抑制癌症转移。姜黄素能抑制血管内皮生长因子、Akt 和 STAT3 等多个下游靶点,从而抑制血液肿瘤的进展。姜黄素会刺激 DNA 损伤,降低癌细胞对照射的抵抗力。此外,姜黄素还能提高血液肿瘤,尤其是骨髓瘤的药物敏感性。为了靶向输送姜黄素并改善其药代动力学和抗癌特性,人们开发了含有姜黄素和其他抗癌剂的纳米结构。
Curcumin in treatment of hematological cancers: Promises and challenges
Hematological cancers include leukemia, myeloma and lymphoma and up to 178.000 new cases are diagnosed with these tumors each year. Different kinds of treatment including radiotherapy, chemotherapy, immunotherapy and stem cell transplantation have been employed in the therapy of hematological cancers. However, they are still causing death among patients. On the other hand, curcumin as an anti-cancer agent for the suppression of human cancers has been introduced. The treatment of hematological cancers using curcumin has been followed. Curcumin diminishes viability and survival rate of leukemia, myeloma and lymphoma cells. Curcumin stimulates apoptosis and G2/M arrest to impair progression of tumor. Curcumin decreases levels of matrix metalloproteinases in suppressing cancer metastasis. A number of downstream targets including VEGF, Akt and STAT3 undergo suppression by curcumin in suppressing progression of hematological cancers. Curcumin stimulates DNA damage and reduces resistance of cancer cells to irradiation. Furthermore, curcumin causes drug sensitivity of hematological tumors, especially myeloma. For targeted delivery of curcumin and improving its pharmacokinetic and anti-cancer features, nanostructures containing curcumin and other anti-cancer agents have been developed.